Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 9/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984745 | 0.93 | BTK (0.39) | KDM1AKDM2BKDM4CBTKTAS1R3 | |
| SCHEMBL984583 | 0.91 | LMNA (0.38) | KDM1AKDM2BKDM4CBTKTAS1R3 | |
| SCHEMBL981511 | 0.91 | KDM1A (0.42) | KDM1ASMYD3KDM2BKDM4CTAS1R3 | |
| SCHEMBL985165 | 0.90 | BTK (0.43) | KDM1ASMYD3BTK | |
| SCHEMBL986107 | 0.90 | BTK (0.43) | KDM1ASMYD3BTK | |
| SCHEMBL986033 | 0.90 | CSNK2A2 (0.38) | KDM1AKDM2BKDM4CBTKTAS1R3 | |
| SCHEMBL986034 | 0.90 | CSNK2A2 (0.38) | KDM1AKDM2BKDM4CBTKTAS1R3 | |
| SCHEMBL985596 | 0.90 | SMYD3 (0.41) | KDM1ASMYD3BTKPBKHPGD | |
| SCHEMBL985060 | 0.90 | HPGD (0.40) | KDM2BKDM4CBTKTAS1R3TAS1R1 | |
| SCHEMBL985299 | 0.90 | BTK (0.37) | KDM1AKDM2BKDM4CBTKTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | KDM1A 1204/4885SMYD3 1287/4885KDM2B 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.